Table 2.

Clinical Characteristics of the Patients Enrolled in the 2 Groups

Control Group (n=146)RenalGuard Group (n=146)
Serum creatinine, median (range), mg/dL1.79 (1.15–3.85)1.80 (1.15–4.78)
eGFR, mL[ · ]min−1 · 1.73 m−232±732±9
Contrast nephropathy risk score12±212±3
    ≤5, n (%)3 (2)2 (1.5)
    ≥6–10, n (%)8 (13)27 (19)
    ≥11–15, n (%)103 (72.5) 95 (67)
    ≥16, n (%) 18 (12.5)17 (12)
Serum urea nitrogen, mg/dL
    Baseline78±3180±35
    After 48 h70±3071±35
Serum sodium, mEq/L
    Baseline140±5140±3
    After 2 h140±5141±4
    After 6 h139±5140±5
    After 24 h139±3141±5
    After 48 h139±6140±5
Serum potassium, mEq/L
    Baseline4.7±0.74.6±0.7
    After 2 h4.4±0.74.1±0.7
    After 6 h4.4±0.64.2±0.6
    After 24 h4.3±0.64.1±0.6
    After 48 h4.3±0.64.2±0.6
Serum magnesium, mg/dL*
    Baseline1.91±0.4
    After 2 h1.71±0.4
    After 6 h1.72±0.4
    After 24 h1.76±0.4
    After 48 h1.83±0.4
  • eGFR indicates estimated glomerular filtration rate.

  • * Serum magnesium was measured in 137 patients.